Cardiac manifestations in antiphospholipid syndrome

Area of Science:

• Cardiology
• Rheumatology
• Immunology

Background:

• Antiphospholipid syndrome (APS) is an autoimmune disorder linked to thrombosis and pregnancy loss.
• Cardiac involvement in APS includes accelerated atherosclerosis, leading to increased cardiovascular mortality, especially in secondary APS associated with lupus.
• Both traditional and autoimmune-inflammatory factors contribute to APS-related atherosclerosis.

Purpose of the Study:

• To review the cardiac manifestations of Antiphospholipid Syndrome (APS).
• To discuss the role of antiphospholipid antibodies (APA) in APS-associated cardiovascular disease.
• To outline prevention and management strategies for cardiovascular risk in APS.

Main Methods:

• Literature review of cardiac manifestations in Antiphospholipid Syndrome.
• Analysis of the role of antiphospholipid antibodies (APA) and other autoantibodies in vascular events.
• Examination of current prevention strategies including pharmacotherapy and lifestyle modifications.

Main Results:

• Accelerated atherosclerosis and cardiovascular disease are primary cardiac concerns in APS, with higher risk in secondary APS.
• Valvular disease (e.g., Libman-Sacks endocarditis) and other conditions like ventricular dysfunction and pulmonary hypertension are also observed.
• Antiphospholipid antibodies (APA) are implicated in the pathogenesis of vascular and cardiac events.

Conclusions:

• APS patients face significant cardiovascular risk, necessitating comprehensive cardiac evaluation.
• Management involves controlling traditional risk factors, pharmacotherapy (statins, aspirin), and potentially anti-inflammatory treatments.
• Early diagnosis, risk factor management, and close monitoring are key to minimizing cardiovascular morbidity and mortality in APS.